221. 抗糸球体基底膜腎炎
[臨床試験数:1,薬物数:3(DrugBank:1),標的遺伝子数:0,標的パスウェイ数:0]
Searched query = "Anti-glomerular basement membrane disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03157037 (ClinicalTrials.gov) | March 1, 2017 | 11/5/2017 | An Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease (GOOD-IDES) | An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES | Anti-Glomerular Basement Membrane Disease | Biological: HMed-IdeS | Mårten Segelmark | Hansa Biopharma AB | Completed | 18 Years | N/A | All | 15 | Phase 2 | Austria;Czechia;Denmark;France;Sweden |